Greenwich LifeSciences Inc.
GLSI
We are a clinical-stage biopharmaceutical company focused on our Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+)…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$25M
▼ -11.2% YoY
Op. Margin
–
ROIC
-896.03%
▼ -762.5pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$13M
▼ -36.4% YoY
Net Debt
-$6M
Net Cash Position
Cash & Equiv.
$6M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with GLSI
Held by ETFs
GLSI is in 5 US ETFs. The largest of them, with GLSI's weight in each:
Greenwich LifeSciences (GLSI) in two numbers
Questions about Greenwich LifeSciences
Does Greenwich LifeSciences (GLSI) pay a dividend?
No. Greenwich LifeSciences (GLSI) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 6 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in GLSI's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing GLSI
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.